Clinical Trial

A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

Name: A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension — clinical trial record (NCT07700875)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.

Trial Details

NCT Number	NCT07700875
Lead Sponsor	Wuhan Createrna Science and Technology Co., Ltd
Conditions	Essential Hypertension
Enrollment	391 participants
Start Date	2022-12-29
Primary Completion	2023-08-20 (estimated)
Study Completion	2023-09-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-14